Advertisement

Drugs

, Volume 64, Issue 5, pp 511–519 | Cite as

Ciclesonide

  • Neil A. Reynolds
  • Lesley J. Scott
Adis Drug Profile

Abstract

  • ▴ Ciclesonide is an inhaled corticosteroid (delivered via a hydrofluoroalkane metered-dose inhaler) that is converted to an active metabolite, desisobutyryl-ciclesonide, in the lung, thereby minimising effects on endogenous cortisol.

  • ▴ In two 12-week, randomised studies in patients with asthma, ciclesonide 80 or 320μg once daily was at least as effective as budesonide 400 μg/day at increasing forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline; ciclesonide 320μg daily was significantly more effective than budesonide 400μg once daily in one study.

  • ▴ In a randomised, double-blind study in patients with asthma controlled with high-dosages of inhaled corticosteroids, FEV1 and FVC decreased significantly from baseline at 12 weeks in patients receiving ciclesonide 320μg daily or budesonide 400μg daily; peak expiratory flow values decreased significantly only in patients receiving budesonide.

  • ▴ Inhaled ciclesonide 80 or 320μg daily improved asthma symptom scores and decreased the use of rescue medication by a similar, significant amount to budesonide 400 μg/day in two 12-week studies.

  • ▴ Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown.

Keywords

Asthma Budesonide Force Vital Capacity Fluticasone Propionate Peak Expiratory Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Thorax 2003 Feb; 58 Suppl. 1: 1–94CrossRefGoogle Scholar
  2. 2.
    Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002 Oct; 360: 1313–22PubMedCrossRefGoogle Scholar
  3. 3.
    National Heart, Lung and Blood Institute. Expert panel report: guidelines for the diagnosis and management of asthma — update on selected topics 2002. J Allergy Clin Immunol 2002 Nov; 110(5): S141–219CrossRefGoogle Scholar
  4. 4.
    Mobley JL, Chin JE, Richards IM. Glucocorticosteroids, old and new: biological function and use in the treatment of asthma. Expert Opin Invest Drugs 1996; 5(7): 871–84CrossRefGoogle Scholar
  5. 5.
    Larsen BB, Nielsen LP, Engelstätter R, et al. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003 Mar; 58(3): 207–12PubMedCrossRefGoogle Scholar
  6. 6.
    Weinbrenner A, Hiineke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002 May; 87(5): 2160–3PubMedCrossRefGoogle Scholar
  7. 7.
    Janson C, Chinn S, Jarvis D, et al. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 1795–802PubMedCrossRefGoogle Scholar
  8. 8.
    The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998; 12: 315–35CrossRefGoogle Scholar
  9. 9.
    Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001 Jun; 17(6): 1083–8PubMedCrossRefGoogle Scholar
  10. 10.
    Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999 Jul; 160(1): 237–43PubMedGoogle Scholar
  11. 11.
    Rohatagi S, Arya V, Zech K, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43: 365–78PubMedCrossRefGoogle Scholar
  12. 12.
    Georgitis JW. The 1997 Asthma management guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999 Jan; 115: 210–7PubMedCrossRefGoogle Scholar
  13. 13.
    Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1–S53PubMedGoogle Scholar
  14. 14.
    Kanniess F, Richter K, Böhme S, et al. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001; 14(2): 141–7PubMedCrossRefGoogle Scholar
  15. 15.
    Hansel T, Engelstätter R, Benezet O, et al. Once daily ciclesonide (80μg or 320μg) is equally effective as budesonide 200μg given twice daily: a 12-week study in asthma patients [abstract no P2639]. Eur Respir J 2003; 22 Suppl. 45: 410. Plus poster presented at the 13th Annual Congress of the European Respiratory Society; 2003 Sep 27–Oct 1; ViennaGoogle Scholar
  16. 16.
    Richter K, Nielsen-Gode D, Biberger C, et al. Oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in asthmatics [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A189Google Scholar
  17. 17.
    Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide [abstract no. 598]. J Allergy Clin Immunol 2003 Feb; 111 (2 Suppl.): S218CrossRefGoogle Scholar
  18. 18.
    Mealy NE, Bayès M, Castañer J. Ciclesonide. Treatment of allergic rhinitis: antiallergy/antiasthmatic. Drugs Future 2001; 26(11): 1033–9CrossRefGoogle Scholar
  19. 19.
    Belvisi MG, Bundschuh DS, Stoeck M, et al. Pre-clinical pharmacological profile of ciclesonide, a novel corticosteroid for the treatment of asthma [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A589Google Scholar
  20. 20.
    Stoeck M, Hatzelmann A, Belvisi MG, et al. In vitro anti-inflammatory activity of the new glucocorticoid ciclesonide in human cells [abstract no P679].. Eur Respir J 2001 Sep; 18 Suppl. 33: 95sGoogle Scholar
  21. 21.
    Belvisi M, Bundschuh D, Stoeck M, et al. Ciclesonide, a novel “on site activated” inhaled corticosteroid with potent anti-inflammatory actions in the airways [abstract no. 59]. J Allergy Clin Immunol 2002 Jan; 109 (1 Suppl.): S37. Plus poster presented at American Acadamy of Allergy, Asthma and Immunology; 2002 Mar 1–6; New YorkCrossRefGoogle Scholar
  22. 22.
    Bundschuh DS, Riedel R, Hatzelmann A, et al. Efficacy and safety profile of the novel on-site activated corticosteroid ciclesonide [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A588Google Scholar
  23. 23.
    Bundschuh DS, Marx D, Hatzelmann A, et al. Pre-clinical anti-inflammatory activity and safety profile of the novel glucorticoid ciclesonide [abstract no1013]. Eur Respir J 2001 Sep; 18 Suppl. 33: 147sGoogle Scholar
  24. 24.
    Nonaka T, Sugiyama H, Taneda M, et al. Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro [abstract no P652]. Eur Respir J 2002 Sep; 20 Suppl. 38: 91sGoogle Scholar
  25. 25.
    Belvisi MG, Bundschuh DS, Stoeck M, et al. Pre-clinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma [abstract noP682]. Eur Respir J 2001 Sep; 18 Suppl. 33: 95sGoogle Scholar
  26. 26.
    Pauwels RA, Derom E, Van De Velde V, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A768. Plus poster presented at the 98th International Conference of the American Thoracic Society; May 4–7; AtlantaCrossRefGoogle Scholar
  27. 27.
    O’Connor B, Sips P, Engelstätter R, et al. Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A767Google Scholar
  28. 28.
    O’Connor BJ, Kilfeather S, Cheung D, et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks [abstract no 2579]. Eur Respir J 2002 Sep; 20 Suppl. 38: 406sGoogle Scholar
  29. 29.
    Engelstätter R, Langdon C, Bethke T, et al. Efficacy of ciclesonide after 12-week treatment of bronchial asthma. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A766Google Scholar
  30. 30.
    Chapman KR, D’Urzo AD, Oedekoven C, et al. Effects of ciclesonide versus placebo on lung function after 12 weeks of treatment in patients with asthma [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A767Google Scholar
  31. 31.
    Chapman KR, Patel P, Boulet LP, et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur Respir J 2002 Sep; 20 Suppl. 38: 373–4sGoogle Scholar
  32. 32.
    Boulet L-P, Engelstätter R, Magyar P, et al. Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma [abstract no. A1508]. Am J Respir Crit Care Med 2003; 167. Plus poster presented at the 99th International Conference of the American Thoracic Society; 2003 May 16–21; SeattleGoogle Scholar
  33. 33.
    Ukena D, Biberger C, von Behren, et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study [abstract no. P2640]. Eur Respir J 2003; 22 Suppl. 45: S45. Plus poster presented at the 13th Annual Congress of the European Respiratory Society; 2003 Sep 27–Oct 1; ViennaGoogle Scholar
  34. 34.
    Nave R, Bethke TD, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects [abstract no P749]. Eur Respir J 2002 Sep; 20 Suppl. 38: 110sGoogle Scholar
  35. 35.
    Dahl R, Nielsen LP, Christensen MB, et al. Ciclesonide — an inhaled corticosteroid prodrug — inhibits allergen induced early and late phase reactions [abstract no P0475]. Eur Respir J 1998 Sep; 12 Suppl. 28: 62sGoogle Scholar
  36. 36.
    LaForce CF, Baker JW, Amin D, et al. Ciclesonide, a novel inhaled steroid, has no effect on hypothalamic-pituitary-adrenal-axis function in mild-to-moderate asthmatics [abstract no. 596]. J Allergy Clin Immunol 2003 Feb; 111 (2 Suppl.): S218CrossRefGoogle Scholar
  37. 37.
    Nave R, Bethke TD, van Marie SP, et al. Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects [abstract no P745]. Eur Respir J 2002 Sep; 20 Suppl. 38: 109sGoogle Scholar
  38. 38.
    Bethke TD, Nave R, Zech K, et al. Pharmacokinetics of ciclesonide and its active principle in asthma patients and healthy subjects after single-dose inhalation [abstract no. 593]. J Allergy Clin Immunol 2003 Feb; 111 (2 Suppl.): 217CrossRefGoogle Scholar
  39. 39.
    Drollmann A, Hasselquist BE, Boudreau RJ, et al. Ciclesonide shows high lung deposition in 2D and 3D-imaging. Am J Respir Crit Care Med 2002 Apr; 165 (8 Pt 2): A188Google Scholar
  40. 40.
    Bethke TD, Boudreau RJ, Hasselquist BE, et al. High lung deposition of ciclesonide in 2D-and 3D-imaging [abstract no P746]. Eur Respir J 2002 Sep; 20 Suppl. 38: 109sGoogle Scholar
  41. 41.
    Altana Pharma. Pharmaceuticals research and development [online]. Available from URL: http://www.altana.com [Accessed 2003 Aug 29]

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations